Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban;Relevanz von P-Glykoprotein in der Schlaganfallprävention mit Dabigatran, Rivaroxaban und Apixaban

Herz

Volumn 40, Issue 2, 2015, Pages 140-145

  Stollberger C ^a   Finsterer, J ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Anticoagulation; Atrial fibrillation; Blood brain barrier; Drug drug interaction; Proton pump inhibitors

Indexed keywords

ANTITHROMBIN; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; MULTIDRUG RESISTANCE PROTEIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN;

ATRIAL FIBRILLATION; DRUG INTERACTION; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; DRUG INTERACTIONS; FACTOR XA INHIBITORS; HUMANS; P-GLYCOPROTEIN; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; TREATMENT OUTCOME;

EID: 84939956529     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-014-4188-9     Document Type: Review

References (45)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
2. Patel MR, Mahaffey KW, Garg J, Pan G et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 65:981–992
4. Härtter S, Sennewald R, Nehmiz G, Reilly P (2013) Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 75:1053–1062
5. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T et al (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372–380
6. Wang L, He K, Maxwell B, Grossmann SJ et al (2011) Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 39:256–264
7. Aller SG, Yu J, Ward A, Weng Y et al (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722
8. Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216–237
9. Shen S, Zhang W (2010) ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci 21:29–53
10. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29
11. Gong IY, Mansell SE, Kim RB (2013) Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol 112:164–170
12. Delavenne X, Ollier E, Basset T, Bertoletti L et al (2013) A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 78:107–113
13. Taubert D, Beckerath N von, Grimberg G, Lazar A et al (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486–501
14. Wessler JD, Grip LT, Mendell J, Giugliano RP (2013) The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 61:2495–2502
15. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH (2007) Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927–941
16. Okura T, Ibe M, Umegaki K et al (2010) Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 33:255–259
17. Jin MJ, Han HK (2010) Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. J Food Sci 75:H93–H96
18. El-Readi MZ, Hamdan D, Farrag N et al (2010) Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur J Pharmacol 626:139–145
19. Ahmed IS, Hassan MA, Kondo T (2013) Effect of lyophilized grapefruit juice on P-glycoprotein-mediated drug transport in-vitro and in-vivo. Drug Dev Ind Pharm (Epub ahead of print)
20. Fan L, Tao GY, Wang G, Chen Y et al (2009) Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother 43:944–949
21. Kumar KK, Priyanka L, Gnananath K et al (2014) Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats. Eur J Drug Metab Pharmacokinet (Epub ahead of print)
22. Angelini A, Di Ilio C, Castellani ML et al (2010) Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents 24:197–205
23. 1 on the intestinal absorption of geniposide by the everted rat gut sac model. J Ethnopharmacol 142:136–143
24. Colombo D, Lunardon L, Bellia G (2014) Cyclosporine and herbal supplement interactions. J Toxicol (Epub 2014 Jan 12)
25. Bogacz A, Mikołajczak PŁ, Mikołajczak PŁ, Rakowska-Mrozikiewicz B et al (2014) The influence of soybean extract on the expression level of selected drug transporters, transcription factors and cytochrome P450 genes encoding phase I drug-metabolizing enzymes. Ginekol Pol 85:348–353
26. Zhai XJ, Shi F, Chen F, Lu YN (2013) Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition. Food Chem Toxicol 62:323–328
27. Si M, Zhao J, Li X et al (2013) Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Chin Med J 126:4116–4123
28. Chieli E, Romiti N, Rodeiro I, Garrido G (2010) In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. Chem Biol Interact 186:287–294
29. Gao LN, Zhang Y, Cui YL, Yan K (2014) Evaluation of genipin on human cytochrome P450 isoenzymes and P-glycoprotein in vitro. Fitoterapia 98:130–136
30. Yu CP, Hsieh YW, Lin SP et al (2014) Potential modulation on P-glycoprotein and CYP3A by soymilk and miso: in vivo and ex-vivo studies. Food Chem 149:25–30
31. Schiffman SS, Rother KI (2013) Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health B Crit Rev 16:399–451
32. Ieiri I (2012) Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 27:85–105
33. Sadeque AJ, Wandel C, He H, Shah S et al (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231–237
34. Kharasch ED, Hoffer C, Whittington D (2004) The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 57:600–610
35. Baltes S, Gastens AM, Fedrowitz M, Potschka H et al (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52:333–346
36. Zhang C, Kwan P, Zuo Z, Kwan P et al (2012) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 64:930–942
37. Jungbauer L, Dobias C, Stöllberger C, Weidinger F (2010) The frequency of prescription of P-glycoprotein affecting drugs in atrial fibrillation. J Thromb Haemost 8:2069–2070
38. Wadelius M, Sörlin K, Wallerman O, Karlsson J et al (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4:40–48
39. Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G et al (2012) Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 74:490–500
40. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9:2168–2175
41. Mueck W, Kubitza D, Becka M (2013) Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 76:455–466
42. Pfeilschifter W, Luger S, Brunkhorst R et al (2013) The gap between trial data and clinical practice—an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 36:115–119
43. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J (2013) Cerebral haemorrhage under rivaroxaban. Int J Cardiol 167:e179–e181
44. Zhang D, He K, Herbst JJ, Kolb J et al (2013) Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos 41:827–835
45. Beyer-Westendorf J, Ageno W (2014) Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 113 (Epub ahead of print)